Full-Time

Vice President

Regulatory Affairs

Confirmed live in the last 24 hours

Tango Therapeutics

Tango Therapeutics

51-200 employees

Develops targeted cancer therapies using synthetic lethality

Biotechnology
Healthcare

Expert

Boston, MA, USA

Office located at 201 Brookline Avenue, Fenway area of Boston, Massachusetts.

Category
Risk & Compliance
Legal & Compliance
Requirements
  • Bachelor’s degree in life sciences, biochemistry, chemistry, biology or related pharmaceutical fields including biochemical engineering; advanced degree is desirable
  • Minimum 15 years of relevant biopharmaceutical industry experience, with at least 10 years' experience in Regulatory Affairs and deep experience in oncology; precision medicine given preference
  • Experience interacting with regulatory health authorities and experience with submitting CTA/IND and BLA/MAA filings, ideally in an area related to oncology
  • Familiarity with Chemistry, Manufacturing, and Control (CMC), Pharmacovigilance and Quality, related matters, and their intersection with Regulatory Affairs
  • Strong knowledge of drug and small molecule development regulations and guidelines including ICH, FDA, and EMA
  • Excellent written and verbal communication skills, strong technical knowledge, including regulatory writing
  • Strong leadership qualities including strategic thinking, innovation, mentoring, collaboration, etc
  • Solid working knowledge of drug development process and regulatory requirements in US and EU, Japan, Canada, and ROW a plus
  • Detail oriented; science-based reasoning skills
  • Ability to work in a fast-paced, start-up environment
  • Ability to work effectively in a collaborative team-oriented environment
  • Independently motivated and results oriented
Responsibilities
  • You will provide global regulatory leadership to support development of multiple, innovative therapies for oncology
  • Maintain, manage, and develop a high performing regulatory team
  • You will partner with key team members to develop strategies to advance our molecules from IND through pivotal studies and registration, leveraging a deep understanding of the landscape of precision oncology
  • Drive the planning and implementation of meetings with regulatory authorities and effectively represent Tango with regulatory interactions
  • Understand and interpret complex scientific issues for assigned projects as they relate to regulatory requirements and strategy for assigned projects, and provide knowledge and expertise to guide the team in appropriate regulatory strategy
  • Proactively identify regulatory issues; offer creative solutions and strategies, including risk mitigation
  • Manage and implement planning, authoring, and submission of high-quality briefing documents and clinical trial applications in the US, EU, Japan, and ROW
  • Accountable for all submissions and approvals for assigned project(s)
  • Direct point of contact with health authorities, lead and manage FDA/global health authority interactions/meetings for project responsibilities; prepare and submit responses to queries
  • Drive adherence to global regulatory guidelines relevant for the development of oncology products; author, review, and approve, as necessary, internal documentation to ensure conformance with regulations and existing regulatory approvals
  • Partner and work closely with Nonclinical, CMC, Quality, and Clinical to ensure achievement of submission deadlines, and obtain timely approvals of clinical trial applications
  • Monitor global regulatory guidelines and anticipate trends that may impact the regulatory environment to strengthen product development plan(s) and adopt regulatory strategies in a timely manner
  • Identify and implement processes, procedures, and systems appropriate for company size and stage
  • Provide Regulatory assessment to due diligence teams in terms of risks, requirements, and opportunities associated with collaborations
  • Additional duties and responsibilities as required

Tango Therapeutics develops targeted cancer treatments using the principle of synthetic lethality, which allows them to design drugs that kill cancer cells while leaving healthy cells unharmed. Their approach focuses on the interaction between genes, where the loss of both genes leads to cell death, but the loss of just one does not. This method enables them to create therapies that are more precise in targeting tumors. Tango operates in the oncology market, primarily serving healthcare providers and pharmaceutical companies interested in advanced cancer therapies. They collaborate with larger pharmaceutical firms, like Gilead Sciences, to co-develop these treatments, which helps them secure funding and speed up the development process. Tango's goal is to bring next-generation targeted immunotherapies to market, supported by a strong team and strategic partnerships.

Company Stage

IPO

Total Funding

$341.4M

Headquarters

Cambridge, Massachusetts

Founded

2017

Growth & Insights
Headcount

6 month growth

1%

1 year growth

17%

2 year growth

87%
Simplify Jobs

Simplify's Take

What believers are saying

  • FDA's Fast Track designation for TNG462 suggests a favorable regulatory environment.
  • Growing interest in synthetic lethality boosts Tango's market potential.
  • Increasing prevalence of MTAP-deleted tumors presents a significant market opportunity.

What critics are saying

  • Discontinuation of TNG348 due to liver toxicity may impact investor confidence.
  • Reliance on partnerships for financial support poses a risk if altered or terminated.
  • Intensifying competition in precision oncology could affect Tango's market share.

What makes Tango Therapeutics unique

  • Tango leverages synthetic lethality to target cancer cells while sparing healthy ones.
  • Their focus on tumor suppressor gene loss is a novel approach in oncology.
  • Collaboration with Gilead Sciences accelerates development and commercialization of therapies.

Help us improve and share your feedback! Did you find this helpful?